Prevalence and detection of low-allele-fraction variants in clinical cancer samples.

Prevalence and detection of low-allele-fraction variants in clinical cancer samples.
复制标题

DOI:
10.1038/s41467-017-01470-y
复制
发表时间:
2017-11-09
影响因子:
16.6
通讯作者:
Park WY
Park WY
中科院分区:
综合性期刊1区
文献类型:
--
作者:
Shin HT;Choi YL;Yun JW;Kim NKD;Kim SY;Jeon HJ;Nam JY;Lee C;Ryu D;Kim SC;Park K;Lee E;Bae JS;Son DS;Joung JG;Lee J;Kim ST;Ahn MJ;Lee SH;Ahn JS;Lee WY;Oh BY;Park YH;Lee JE;Lee KH;Kim HC;Kim KM;Im YH;Park K;Park PJ;Park WY

文献摘要

参考文献

被引文献

相似文献

使用高通量测序准确检测基因组改变是精确癌症医学的重要组成部分。我们描述了体细胞单核苷酸变异和索引的变异等位基因分数(VAFs),这些变异等位基因分数跨越5095个临床样本,使用定制面板,CancerSCAN进行分析。我们的研究结果表明,相当一部分临床可操作的变异具有低VAFs,通常是由于低肿瘤纯度和治疗诱导的突变。在EGFR、KRAS、PIK3CA和BRAF热点中,5% VAF以下的突变百分比分别为16%、11%、12%和10%,其中EGFR T790M为24%,PIK3CA E545为17%。对于临床相关性,我们描述了两例患者,尽管低VAF突变,靶向治疗仍获得缓解。我们还描述了必要的读取深度,以达到与当前实验室分析相当的灵敏度和特异性。这些结果表明,通过足够的测序覆盖率和精心调整的算法捕获热点地区的低VAF突变对于临床分析是必不可少的。高通量测序用于鉴定癌症患者的体细胞变异。在这里,作者对5095个临床样本进行了基于小组的分析,并证明许多临床可操作的变异具有低变异等位基因分数,需要具有高检测灵敏度的分析。
Accurate detection of genomic alterations using high-throughput sequencing is an essential component of precision cancer medicine. We characterize the variant allele fractions (VAFs) of somatic single nucleotide variants and indels across 5095 clinical samples profiled using a custom panel, CancerSCAN. Our results demonstrate that a significant fraction of clinically actionable variants have low VAFs, often due to low tumor purity and treatment-induced mutations. The percentages of mutations under 5% VAF across hotspots in EGFR, KRAS, PIK3CA, and BRAF are 16%, 11%, 12%, and 10%, respectively, with 24% for EGFR T790M and 17% for PIK3CA E545. For clinical relevance, we describe two patients for whom targeted therapy achieved remission despite low VAF mutations. We also characterize the read depths necessary to achieve sensitivity and specificity comparable to current laboratory assays. These results show that capturing low VAF mutations at hotspots by sufficient sequencing coverage and carefully tuned algorithms is imperative for a clinical assay. High-throughput sequencing is used to identify somatic variants in cancer patients. Here, the authors perform panel-based profiling of 5095 clinical samples and demonstrate that many clinically-actionable variants have low variant allele fractions, requiring assays with high detection sensitivity.
DOI: 10.1056/nejmoa040938
发表时间: 2004-05-20
影响因子: 158.5
作者:
Lynch, TJ;Bell, DW;Haber, DA
通讯作者: Haber, DA
DOI: 10.1038/nprot.2009.86
发表时间: 2009-01-01
期刊: NATURE PROTOCOLS
影响因子: 14.8
作者:
Kumar, Prateek;Henikoff, Steven;Ng, Pauline C.
通讯作者: Ng, Pauline C.
宇宙(癌症中的体细胞突变目录)数据库和网站。
DOI: 10.1038/sj.bjc.6601894
发表时间: 2004-07-19
影响因子: 8.8
作者:
Bamford, S;Dawson, E;Forbes, S;Clements, J;Pettett, R;Dogan, A;Flanagan, A;Teague, J;Futreal, PA;Stratton, MR;Wooster, R
通讯作者: Wooster, R
DOI: 10.18632/oncotarget.8074
发表时间: 2016-04-26
期刊: Oncotarget
影响因子: --
作者:
Lee B;Lee T;Lee SH;Choi YL;Han J
通讯作者: Han J
DOI: 10.1056/nejmoa1411817
发表时间: 2015-04-30
影响因子: 158.5
作者:
Jaenne, Pasi A.;Yang, James Chih-Hsin;Ranson, Malcolm
通讯作者: Ranson, Malcolm